CG
CGS.AU Cogstate Ltd
- Market cap
- AUD 596M
- P/E
- 34.5x
- P/B
- 7.21x
- ROE
- 20.9%
- Dividend yield
- 1.16%
- Fundamental score
- 3.2/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is CGS.AU undervalued?
Graham numberThe Graham number of Cogstate Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cogstate Ltd fundamental analysis
14 of 22 checks passedROE 2/2
High return on equity (20.9%), above 20%.
ROA 1/1
Return on assets (15.6%) is above the industry median (-45.6%).
Profit Consistency 2/2
Profitable for 6 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (79.5%) is above the 5-year average (17.6% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (79.5%) is above the industry median (18.9%).
Revenue Growth 2/2
Revenue grew 14.5% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (0.6%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 667.3x against interest expense, well covered.
PE vs Market 0/1
PE (34.5x) is above the market median (15.0x).
PE vs Industry 0/1
PE (34.5x) is above the industry median (11.1x).
PBV 0/1
Price to book (7.2x) is above the industry median (5.7x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 248.7, limit 22.5).
PEG 0/1
PEG on 5-year earnings growth is 1.96, above 1.
Dividend Yield 0/2
Dividend yield (0.5%) is in the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 18.9%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Cogstate Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cogstate Ltd
Cogstate Limited, a neuroscience solutions company, engages in the creation, validation, and commercialization of digital brain health assessments worldwide. The company offers digital cognitive assessment, endpoint data quality (rater services), remote assessment, scientific consulting, healthcare cognitive screening, and research and academic collaboration solutions for various therapeutic areas, including Alzheimer's disease and dementia, preclinical Alzheimer's disease, …
Full company profileCogstate Ltd financial statements
Cogstate Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 35.0M | 27.5M | 21.8M | 23.5M | 32.7M | 45.0M | 39.9M | 43.4M | 33.3M | 59.9M |
| Gross Profit | 5.18M | 5.52M | 1.47M | 1.36M | 7.81M | 14.9M | 8.16M | 24.7M | 20.1M | 20.2M |
| Operating Income | -481K | 178K | -5.85M | -1.64M | 3.86M | 10.9M | 2.27M | 2.58M | 7.07M | 12.4M |
| EBITDA | 542K | 820K | -3.35M | -848K | 6.21M | 12.7M | 4.90M | 7.61M | 12.1M | 15.5M |
| Net Income | -853K | -538K | -2.44M | -2.02M | 5.27M | 7.13M | 3.52M | 3.63M | 6.65M | 12.2M |
| EPS | -0.01 | 0.00 | -0.02 | -0.01 | 0.03 | 0.04 | 0.02 | 0.02 | 0.04 | 0.07 |
| Balance Sheet | ||||||||||
| Total Assets | 21.9M | 18.7M | 19.2M | 32.1M | 51.4M | 58.4M | 53.9M | 57.8M | 64.8M | 78.0M |
| Total Liabilities | 7.42M | 7.08M | 9.09M | 16.5M | 29.6M | 25.5M | 16.3M | 16.9M | 16.9M | 19.8M |
| Shareholders' Equity | 14.4M | 11.6M | 10.1M | 15.6M | 21.8M | 32.9M | 37.6M | 27.3M | 47.9M | 58.2M |
| Cash & Short-term Investments | 9.33M | 4.35M | 3.20M | 10.4M | 23.6M | 30.6M | 28.6M | 30.1M | 35.6M | 34.8M |
| Total Debt | - | 81.0K | 503K | 5.05M | 1.74M | 1.41M | 378K | 673K | 639K | 359K |
| Cash Flow | ||||||||||
| Operating Cash Flow | 3.24M | -75.0K | 425K | 1.06M | 16.1M | 9.73M | 654K | 5.78M | 11.5M | 9.69M |
| Capital Expenditure | 1.46M | 2.72M | 2.39M | 3.14M | 3.28M | 3.38M | 2.18M | 1.92M | 3.07M | 526K |
| Free Cash Flow | 1.78M | -2.80M | -1.96M | -2.08M | 12.9M | 5.87M | -1.01M | 4.75M | 8.40M | 9.17M |
| Ratios | ||||||||||
| ROE | -5.9% | -4.6% | -24.2% | -13.0% | 24.2% | 21.7% | 9.4% | 13.3% | 13.9% | 20.9% |
| ROA | -3.9% | -2.9% | -12.7% | -6.3% | 10.3% | 12.2% | 6.5% | 6.3% | 10.3% | 15.6% |
| Net Profit Margin | -2.4% | -2.0% | -11.2% | -8.6% | 16.1% | 15.9% | 8.8% | 8.4% | 20.0% | 20.3% |
| Debt to Equity | - | 0.01x | 0.05x | 0.32x | 0.08x | 0.04x | 0.01x | 0.02x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cogstate Ltd dividends
- Dividend yield
- 1.16%
- Forward dividend
- 0.04 AUD
- Payout ratio
- 18.9%
- Ex-dividend date
- Aug 21, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 2.30M | 0.01 | 18.9% |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 1.08M | 0.01 | 15.1% |
| 2021 | - | - | - |
| 2020 | USD 3.23M | 0.02 | - |
| 2019 | USD 1.71M | 0.01 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.006:1 on Feb 27, 2006.
Who owns Cogstate Ltd
- Insiders 40.36%
- Institutions 16.83%
- Public & others 42.81%
- Shares outstanding 173M
- Free float 125M
Cogstate Ltd company profile
- Company name
- Cogstate Ltd
- Ticker
- CGS.AU
- ISIN
- AU000000CGS8
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 160
- Fiscal year end
- June
- Address
- 367 Collins Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9664 1300
- Website
- cogstate.com
About Cogstate Ltd
Cogstate Limited, a neuroscience solutions company, engages in the creation, validation, and commercialization of digital brain health assessments worldwide. The company offers digital cognitive assessment, endpoint data quality (rater services), remote assessment, scientific consulting, healthcare cognitive screening, and research and academic collaboration solutions for various therapeutic areas, including Alzheimer's disease and dementia, preclinical Alzheimer's disease, pediatrics and rare disease, Parkinson's disease, multiple sclerosis, schizophrenia, oncology, safety, and sleep and mood disorders. It also designs and provides quality assurance services in clinical trials focused on the administration, scoring, and recording of conventional brain health assessments. In addition, it develops a tool for primary care physicians and/or hospitals to assess cognitive decline. Its technology and associated services are used to quantify the effect of disease and drugs, devices, or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The company serves biopharmaceutical companies, academic institutions, physicians, and patients. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.
Cogstate Ltd management
8- Mr. Bradley John O'Connor B.Bus, C.A.CEO, MD & Executive Director
- Mr. Darren Watson C.A.CFO & Joint Company Secretary
- Dr. Pamela Ventola Ph.D.Chief Science Officer
- Ms. Rachel ColiteExecutive VP of Clinical Trials
- Prof. Paul Maruff BBSc (Hons), Ph.D.Founder & Chief Innovation Officer
- Mr. Kenneth BillardChief Commercial Officer
- Mr. David James Franks BEc, C.A., F Fin, J.P.Joint Company Secretary · born 1970
- Dr. Luka Lucic Ph.D.Senior Director of Clinical Science in Psychiatry